Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution.
Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution.
复制标题
DOI：
10.1186/s12876-016-0520-6
复制
发表时间：
2016-08-26
影响因子：
2.4
通讯作者：
Quera R
中科院分区：
文献类型：
--
作者：
Díaz-Jiménez D;De la Fuente M;Dubois-Camacho K;Landskron G;Fuentes J;Pérez T;González MJ;Simian D;Hermoso MA;Quera R
ST 2/IL-33通路与溃疡性结肠炎（UC）相关，可溶性ST 2（sST 2）与疾病严重程度相关。我们测试了sST 2作为治疗反应和患者结局的预测标志物的潜在有用性。前瞻性招募了26例活动性UC患者，并根据内镜评分和治疗反应进行分组。在基线和6个月时或当患者表现出临床活动时收集结肠镜活检。在需要补救治疗的患者中重新启动方案。在基线、1、3、6和12个月时收集血液和粪便。通过ELISA测定血清和粘膜ST 2和粪便钙卫蛋白（FC）含量，并与马约临床和内镜分项评分相关。免疫荧光法检测小肠ST 2。应用Wilcoxon符号秩检验和斯皮尔曼相关性（Rs）（p <0.05）。24例患者完成随访。基线和6个月时，应答者的sST 2水平（中位数和范围）分别为173.5 [136.6-274.0]至86.5 [54.6-133.2]（p < 0.05），无应答者为336.3 [211.0-403.2]至385.3 pg/mL [283.4-517.3]。sST 2水平与马约临床和内镜分项评分、粘膜ST 2和FC相关（Rs分别为0.57、0.66、0.74和0.42; p < 0.0001），并显示出与应答者FC相似的趋势。无反应者显示ST 2含量增加，仅限于固有层的细胞浸润。对比性sST 2测量以跟踪对治疗有反应或无反应的UC患者的炎症活性变化，将sST 2（如FC）鉴定为预测UC患者临床结局的有用生物标志物。本文的在线版本（doi：10.1186/s12876-016-0520-6）包含补充材料，可供授权用户使用。
The ST2/IL-33 pathway has been related to ulcerative colitis (UC), and soluble ST2 (sST2), to disease severity. We tested the potential usefulness of sST2 as a predictive marker of treatment response and patients’ outcome. Twenty-six patients with active UC were prospectively recruited and grouped according to an endoscopic score and therapy response. Colonoscopic biopsies were collected at baseline and 6 months or when patients showed clinical activity. The protocol was reinitiated in patients requiring rescue therapy. Blood and stool were collected at baseline, 1, 3, 6 and 12 months. Serum and mucosal ST2, and fecal calprotectin (FC) content were determined by ELISA and correlated to Mayo clinical and endoscopic subscore. Intestinal ST2 was evaluated by immunofluorescence. Wilcoxon signed rank test and Spearman correlations (Rs) were applied (p <0.05). Follow-up was completed in 24 patients. sST2 levels (median and range) varied from 173.5 [136.6–274.0] to 86.5 [54.6–133.2] in responders (p < 0.05), and 336.3 [211.0–403.2] to 385.3 pg/mL [283.4–517.3] in non-responders at baseline and 6 months, respectively. sST2 levels correlated with Mayo clinical and endoscopic subscore, mucosal ST2 and FC (Rs = 0.57, 0.66, 0.74 and 0.42, respectively; p < 0.0001) and showed a trend similar to that of FC in responders. Non-responders revealed an increased ST2 content, restricted to the lamina propria’s cellular infiltrate. Consecutive sST2 measurement to follow changes in inflammatory activity of UC patients who respond or not to treatment identifies sST2, like FC, as a useful biomarker in predicting clinical outcome of UC patients. The online version of this article (doi:10.1186/s12876-016-0520-6) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
11
作者：
通讯作者：
--
影响因子：
8
作者：
Garcia-Sanchez, Valle;Iglesias-Flores, Eva;Gomez-Camacho, Federico
通讯作者：
Gomez-Camacho, Federico
影响因子：
5.8
作者：
Cui, Guanglin;Qi, Haili;Florholmen, Jon
通讯作者：
Florholmen, Jon
影响因子：
8
作者：
Dignass, A.;Van Assche, G.;Travis, S. P. L.
通讯作者：
Travis, S. P. L.
影响因子：
29.7
作者：
Kaser A;Zeissig S;Blumberg RS
通讯作者：
Blumberg RS